On the other hand, the specific architecture of the rectal cancer molecular background may have disrupted the interaction between the use of cetuximab and the KRAS mutation observed in colon cancer, resulting in no effect of the mutation on the response to the specific anti-EGFR drug [34,36,37,38]. This evidence concerns the gene KRAS and malignant colon neoplasm.